FibroBiologics, Inc Common Stock

Yahoo Finance • 21 days ago

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

FibroBiologics, Inc. Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued... Full story

Yahoo Finance • 28 days ago

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron (NASDAQ: LGVN) Key Takeaways: • Avaí B... Full story

Yahoo Finance • 2 months ago

FibroBiologics to Present at the BIO Investment & Growth Summit

FibroBiologics, Inc. HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therape... Full story

Yahoo Finance • 5 months ago

FibroBiologics announces payoff of outstanding debt

* FibroBiologics (FBLG [https://seekingalpha.com/symbol/FBLG]) said on Wednesday that it has paid all amounts outstanding [https://seekingalpha.com/pr/20321143-fibrobiologics-announces-payoff-of-outstanding-debt] under the convertible pr... Full story

Yahoo Finance • 5 months ago

FibroBiologics Announces Payoff of Outstanding Debt

HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeuti... Full story

Yahoo Finance • 5 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeuti... Full story

Yahoo Finance • 5 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeuti... Full story

Yahoo Finance • 5 months ago

After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers

(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates.... Full story

Yahoo Finance • 5 months ago

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session was marked by sharp price movements as... Full story

Yahoo Finance • 6 months ago

FibroBiologics to Present at Bio-Europe 2025

HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 7 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 7 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 8 months ago

FibroBiologics reports 1H results

* FibroBiologics press release [https://seekingalpha.com/pr/20185766-fibrobiologics-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:FBLG [https://seekingalpha.com/symbol/FBLG]): 1H For the six months... Full story

Yahoo Finance • 8 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 9 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 9 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 9 months ago

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 10 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 10 months ago

FibroBiologics to Present at the BIO International Convention 2025

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential... Full story

Yahoo Finance • 10 months ago

FibroBiologics announces CFO appointment

* FibroBiologics (NASDAQ:FBLG [https://seekingalpha.com/symbol/FBLG]) announced the appointment of Jason D. Davis, CPA, as chief financial officer, effective immediately.  * Davis most recently served as CFO of Virax Biolabs (VRAX [htt... Full story